Boston Family Office LLC Cuts Position in Zoetis Inc. (NYSE:ZTS)

Boston Family Office LLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 18.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,528 shares of the company's stock after selling 6,365 shares during the period. Boston Family Office LLC's holdings in Zoetis were worth $4,485,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Dunhill Financial LLC raised its holdings in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after acquiring an additional 75 shares in the last quarter. Atlantic Edge Private Wealth Management LLC raised its stake in Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 140 shares in the last quarter. Rakuten Securities Inc. raised its stake in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 166 shares in the last quarter. Murphy & Mullick Capital Management Corp bought a new stake in Zoetis during the fourth quarter valued at approximately $44,000. Finally, Quarry LP grew its stake in Zoetis by 45.9% in the 3rd quarter. Quarry LP now owns 305 shares of the company's stock worth $60,000 after buying an additional 96 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Trading Down 4.9 %

Shares of NYSE ZTS traded down $7.85 during mid-day trading on Friday, hitting $151.76. The stock had a trading volume of 3,611,950 shares, compared to its average volume of 2,595,269. The firm has a market cap of $67.96 billion, a P/E ratio of 27.74, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The business has a 50 day moving average price of $165.71 and a two-hundred day moving average price of $173.43. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion for the quarter, compared to analysts' expectations of $2.30 billion. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.32%. The ex-dividend date is Monday, April 21st. Zoetis's payout ratio is currently 36.56%.

Wall Street Analyst Weigh In

ZTS has been the topic of several research reports. Barclays raised their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. Stifel Nicolaus lowered their price target on Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They issued a "neutral" rating and a $196.00 price objective for the company. Morgan Stanley reduced their price objective on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Finally, Piper Sandler boosted their target price on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $215.90.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares of the company's stock, valued at approximately $2,682,770. This represents a 2.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is currently owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.